Windward Bio reported interim results from the randomized, double-blind Phase II portion of POLARIS-1 in uncontrolled moderate-to-severe asthma and initiated the seamless Phase III portion. Among the first 98 of 147 Phase II participants,…
Inhibrx reported primary-endpoint results from the randomized Phase II portion of HexAgon in first-line, treatment-naive, PD-L1 CPS at least 20 metastatic or unresectable recurrent head and neck squamous-cell carcinoma. INBRX-106 plus pembrolizumab produced a…
Beam Therapeutics presented updated Phase I/II data for BEAM-302, an LNP-delivered adenine base editor intended to correct the SERPINA1 PiZ mutation in alpha-1 antitrypsin deficiency. At 60 mg, six lung-disease and five liver-disease participants…
BrainChild Bio raised a $116 million Series A to fund BCB-276, a B7-H3-directed autologous CAR-T therapy administered into cerebrospinal fluid, through the pivotal-intent Phase II ILLUMINATE study in newly diagnosed diffuse intrinsic pontine glioma….
Editas Medicine appointed Dan Ory, M.D., chief medical officer effective September 8, 2026. He will oversee clinical-development strategy and operations as EDIT-401 approaches clinical development for hyperlipidemia and will support the broader in-vivo gene-editing…
Pharvaris reported that once-daily oral deucrictibant XR reduced mean monthly hereditary-angioedema attack rates by 83% versus placebo in the pivotal Phase III CHAPTER-3 study. The 85-participant trial met its primary endpoint and all multiplicity-controlled…
Roivant and its Pulmovant subsidiary reported a large, internally consistent randomized Phase II signal for once-daily inhaled mosliciguat in pulmonary hypertension associated with interstitial lung disease. At Week 16, pulmonary vascular resistance fell 56.3%…
Upstream Bio presented full Phase II VALIANT results showing that verekitug 100 mg every 12 weeks reduced annualized severe-asthma exacerbations by 56% versus placebo (p
A peer-reviewed Lancet research letter reported the completed dose-escalation cohort of PMB-CT01, an autologous BAFF-R-directed CAR-T therapy, in nine adults with relapsed or refractory B-cell non-Hodgkin lymphoma. Seven of nine patients achieved complete response,…
University of Cambridge and Wellcome Sanger Institute researchers reported an immunocompetent, stepwise model of myeloid-neoplasm evolution. A patient-derived CEBPA N321D mutation created a long-lived premalignant state in Hoxb8-FL murine progenitors; every primary recipient developed…
